• About us
• Contact

Advertisement

Document › Details

Minoryx Therapeutics S.L.. (9/21/18). "Press Release: A Consortium Led by Minoryx Receives €0.8m to Explore Additional Indications for MIN-102".

	Region	Spain (España)
	Organisation	Minoryx Therapeutics S.L.
	Group	Minoryx (Group)
	Organisation 2	Spain (govt)
	Product	leriglitazone (MIN-102)
	Product 2	drug development

El Ministerio de Ciencia, Innovación y Universidades, dentro del Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016, concedió ayuda al proyecto “Búsqueda de nuevas indicaciones terapéuticas en el ámbito de enfermedades neurodegenerativas y mitocondriales para el compuesto PPAR gamma agonista MIN-102” liderado por MINORYX THERAPEUTICS S.L. con número de expediente RTC-2017-5867-1. Este proyecto ha sido financiado por el Ministerio de Ciencia, Innovación y Universidades dentro del Subprograma RETOS-COLABORACIÓN, Convocatoria 2017. El proyecto está cofinanciado por la Unión Europea con el objetivo de promover el desarrollo tecnológico, la innovación y una investigación de calidad.

Record changed: 2023-06-05

Advertisement

More documents for Minoryx (Group)

• [1] Minoryx Therapeutics S.L.. (5/31/22). "Press Release: Minoryx Raises €51 Million to Support Marketing Authorization Application and Launch Preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy". Mataró, Barcelona....
• [2] Minoryx Therapeutics S.L.. (1/26/21). "Press Release: Minoryx Presents Topline Results from Phase 2/3 »ADVANCE« Study Demonstrating Significant Clinical Benefit of Leriglitazone in Adrenomyeloneuropathy (AMN)". Mataró, Barcelona....
• [3] Minoryx Therapeutics S.L.. (3/12/19). "Press Release: Minoryx Therapeutics Appoints Didier Le Normand as Group Chief Financial Officer (CFO) and General Manager of Its Belgian Subsidiary". Mataró, Barcelona & Charleroi....
• [4] Minoryx Therapeutics S.L.. (1/15/19). "Press Release: Minoryx Therapeutics Extends Its Activities in Belgium". Mataró, Barcelona & Charleroi....
• [5] Minoryx Therapeutics S.L.. (12/13/18). "Press Release: Minoryx Therapeutics Announces Early Completion of Patient Randomization in the ADVANCE Trial – a Phase 2/3 Clinical Study of MIN-102 in X-ALD Patients". Mataró, Barcelona....
• [6] Minoryx Therapeutics S.L.. (9/26/18). "Press Release: Minoryx Therapeutics Raises €21.3M in Series B Funding Round". Mataró, Barcelona....
• [7] Minoryx Therapeutics S.L.. (9/5/18). "Press Release: Minoryx Therapeutics Announces Dosing of First US Patient in Phase 2/3 Clinical study of MIN-102 (ADVANCE)". Mataró, Barcelona....
• [8] Minoryx Therapeutics S.L.. (2/20/18). "Press Release: Minoryx Therapeutics Spins Off SEE-Tx Platform into New Company, Gain Therapeutics". Mataró, Barcelona & Lugano....
• [9] Minoryx Therapeutics S.L.. (2/22/17). "Press Release: Minoryx Therapeutics Receives Orphan Drug Designation from the US FDA for Its Lead Candidate MIN-102". Mataró, Barcelona....
• [10] Minoryx Therapeutics S.L.. (2/8/17). "Press Release: Dr Claude Nicaise Joins Minoryx Therapeutics as Independent Board Member". Mataró, Barcelona....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.